Immediate optimal endocrine adjuvant therapy versus standard chemotherapy followed by the same endocrine therapy in pre- or peri-menopausal patients with early hormone receptor-positive breast cancer - the Promise study.

Trial Profile

Immediate optimal endocrine adjuvant therapy versus standard chemotherapy followed by the same endocrine therapy in pre- or peri-menopausal patients with early hormone receptor-positive breast cancer - the Promise study.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 May 2012

At a glance

  • Drugs Anastrozole; Cyclophosphamide; Epirubicin; Fluorouracil; Goserelin
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms PROMISE
  • Most Recent Events

    • 08 May 2012 New source identified and integrated (Netherlands Trial Register; NTR357).
    • 04 Jan 2012 Actual end date (Dec 2011) added as reported by ISRCTN: Current Controlled Trials.
    • 04 Jan 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top